ARTHQ (Arch Therapeutics) Research & Development: $0.77 Mil (TTM As of Jun. 2024)


ARTHQ Arch Therapeutics Inc ARTHQ
12 GF Score
Price $0.00
View Full Analysis

What is Arch Therapeutics Research & Development?

Arch Therapeutics ARTHQ -99.00% 12 Research & Development is $0.77 Mil as of Jun. 2024. GuruFocus rates ARTHQ with a GF Score™ of 12/100.

Research & Development is the aggregate amount of research and development expenses during the year. Arch Therapeutics's Research & Development for the three months ended in Jun. 2024 was $0.16 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 was $0.77 Mil.

Arch Therapeutics  (OTCPK:ARTHQ) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Arch Therapeutics Research & Development Related Terms

Arch Therapeutics Research & Development Historical Data

* Premium members only.

The historical data trend for Arch Therapeutics's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arch Therapeutics Research & Development Chart

Arch Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 2.40 1.61 1.35 1.15 0.67

Arch Therapeutics Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.14 0.20 0.21 0.20 0.16
ARTHQ
12GF Score
Arch Therapeutics Inc ARTHQ
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arch Therapeutics Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.77 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of $0.77 Mil mean?
Arch Therapeutics (ARTHQ) has a Research & Development of $0.77 Mil as of Jun. 2024. Research and development expense is the total cost for research and development activities. View historical data on Arch Therapeutics and its competitors.
Is Arch Therapeutics' Research & Development too high?
Arch Therapeutics' current Research & Development is $0.77 Mil. Overall, Arch Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Arch Therapeutics' Research & Development compare to GRTSQ and MTEM?
Arch Therapeutics' Research & Development of $0.77 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Biotechnology company?
A good Research & Development depends on the Biotechnology industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Arch Therapeutics and its competitors. Arch Therapeutics's current Research & Development is $0.77 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arch Therapeutics stock overvalued right now?
Arch Therapeutics (ARTHQ) has a current Research & Development of $0.77 Mil. The current Research & Development is $0.77 Mil. Arch Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Arch Therapeutics (ARTHQ), the current Research & Development is $0.77 Mil as of Jun. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Arch Therapeutics Business Description

Address 235 Walnut Street, Suite 6, Framingham, MA, USA, 01702
Arch Therapeutics Inc is a development-stage biotechnology company. It focuses on developing products that manage surgery and interventional care faster and safer by using a novel approach to stop bleeding, control leaking, and provide other advantages during surgery and trauma care. The company's primary product candidate, collectively known as the AC5 Devices (AC5), is designed to achieve hemostasis in surgical procedures. The company operates its business operations in the United States.
12GF Score

Get the complete analysis for ARTHQ

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.00
Price